Knee Osteoarthritis
Conditions
Keywords
Mesenchymal stem cells, articular cartilage, tissue engineering, immunomodulation, osteo-arthritis
Brief summary
Articular cartilage can be the seat of many diseases including osteoarthritis and traumatic defaults. The cartilage has no intrinsic ability to repair resulting at long term in function loss in the joints. Currently available treatments are not satisfactory in the long term, the use of mesenchymal stem cells appears to be promising due to their ability to multipotency and immunomodulation properties. This project aims to determine the most appropriate source for regenerative medicine of cartilage stem cells from tissue taken during arthroplasty in patients with osteoarthritis. These cells will be tested for different chondrogenic markers. The success of this project will consider the implementation of a strategy for regenerative medicine in bone and joint diseases.
Interventions
PROCEDUREarthroplasty
Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
Sponsors
Nantes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged over 18 years * Patients with knee osteoarthritis * Patients requiring total knee arthroplasty * Patients who signed the consent form
Exclusion criteria
* Patients aged less than 18 years * Major Patients under guardianship * Pregnant woman * Infectious pathology or progressive tumor * Refusal to participate in the study * State of immunosuppression * Congenital or acquired malformation resulting in a deformation of the knee
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Increased expression of chondrogenic markers | up to 3 years | Increased expression of chondrogenic markers will be Evaluated by different techniques: in vitro: Histology fit for chondrogenic markers, RT-PCR on the following markers aggrecan, type II collagen, Sox9, Comp, type IX collagen in vivo: In a second step, differentiated MSCs are implanted in vivo after combination with a hydrogel subcutaneously in nude mice. The formation of a neo cartilage tissue will be assessed by histology for type II collagen and aggrecan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Increasing secretion of anti-inflammatory molecules in vitro | up to 3 years | Increasing secretion of anti-inflammatory molecules in vitro will be tested by several techniques: Microfluidic cards (TLDA assays) for the analysis of the expression of genes involved in inflammation and in the secretion of anti-inflammatory molecules Inhibition of proliferation of autologous T cells activated or not Assay for anti-inflammatory and pro-inflammatory molecules Analysis of the expression of surface markers by flow cytometry |
Countries
France
Outcome results
None listed